.webp)
.webp)
.webp)
.webp)
Third-party logistics providers (3PLs) receive, store, and ship drugs and devices for manufacturers, wholesale distributors, and dispensers. They do not own the product, and they do not direct the sale.
3PLs are regulated under the Drug Supply Chain Security Act (DSCSA), and most states license them separately from wholesale distributors. When a 3PL facility is not licensed in a state that requires it, every client that relies on that facility loses the ability to ship product into that state until the license is issued.
Federal law defines a 3PL as an entity that provides or coordinates warehousing or other logistics services on behalf of a manufacturer, wholesale distributor, or dispenser, without taking ownership of the product or having responsibility to direct its sale or disposition (21 U.S.C. § 360eee(22)).
State definitions start from the federal definition but are not identical. Some states apply 3PL licensing to prescription devices, OTC products, or reverse logistics. Confirm each state’s definition before deciding which license applies.
A 3PL must hold every license required by its home state and by each state it ships into, and must file the annual DSCSA licensure report with FDA.
Licensure and reporting status determine whether a 3PL is an Authorized Trading Partner (ATP). Manufacturers and wholesale distributors may only work with authorized trading partners, and they verify a 3PL’s status through state license databases and FDA’s reporting database before sending product.
There is no national 3PL license. The DSCSA required FDA to issue national licensing standards for 3PLs. FDA published a proposed rule in February 2022, and its regulatory agenda targets a final rule in June 2028. Until that rule is final and in effect, each state’s program controls.
States take one of three approaches:
Licenses are issued per facility. Each facility that ships into a state with a 3PL program needs its own license from that state.
Controlled substances require additional registration. A 3PL that handles Schedule II through V products must register with the DEA, and some states also require a separate state controlled substance registration.
Every 3PL facility must also report its state licensure information to FDA each year under the DSCSA, a requirement in effect since November 2014. This report is separate from FDA establishment registration. FDA publishes the results in a public database that trading partners use to verify licensure.
Have the following in place before filing state applications.
Home state license. Non-resident boards require proof that the facility is licensed in its home state. If the home state does not license 3PLs, provide written documentation of that. Non-resident boards will hold applications until the home state license is issued.
Designated representative and SOPs. Each facility needs a designated representative or responsible manager who works at the facility and oversees daily operations. Boards verify this. Some states license this individual separately; California requires a licensed Designated Representative-3PL. Written SOPs must describe how the facility actually operates.
Accreditation. Some states require accreditation as a condition of licensure. There are two Accreditation providers for 3PLs, NCDQS QAS Accreditation and NABP Drug Distributor Accreditation (formerly VAWD) Indiana, North Dakota, and Wyoming are the states most consistently identified as requiring it for distribution licenses, and other states accept an NCDQS and/or NABP inspection in place of their own. NCDQS and NABP accreditation is open to 3PLs and runs for three years, but it requires a policy review, licensure verification, and an on-site survey, so it takes time to obtain.
Client agreements. Each client relationship should be governed by a written agreement that states the 3PL does not take title or direct sales, and that assigns responsibility for DSCSA transaction data, recalls, and returns. Federal law and many states require a 3PL to give regulators its client list on request. Each client must hold the licenses its own activities require. If a client is not licensed to distribute into a state, do not ship that client’s product into that state.
Requirements vary by state, but most 3PL applications require:
The following states impose stricter requirements on 3PLs than most.
California issues separate 3PL and non-resident 3PL licenses and does not license 3PLs as wholesalers. A non-resident 3PL must hold a valid home state license at all times and must designate a California-licensed Designated Representative-3PL, or a pharmacist licensed in California, as responsible manager. The Designated Representative-3PL is an individual license with its own application, training, and fingerprinting requirements. California also requires a surety bond. Plan for both the facility application and the individual application.
Arizona requires a 3PL permit for any 3PL that provides logistics services into, within, or from the state. Each facility’s designated representative must hold an Arizona fingerprint clearance card, submitted with the application and again whenever the designated representative changes. On request, the 3PL must give the Board a list of every manufacturer, wholesale distributor, dispenser, and DME supplier it serves.
Kentucky requires a separate license for each 3PL facility. The Board of Pharmacy decides licensure product by product: under its published guidance, a single drug-related item in the product mix requires a permit, even if the facility otherwise handles only devices.
Applications are delayed for four reasons: incomplete submissions, slow responses to deficiency notices, inconsistencies between the application and supporting documents, and classification problems.
Classification problems are specific to 3PLs. If a service agreement, SOP, or invoice shows the 3PL taking title or directing sales, the board will treat the applicant as a wholesale distributor. Every document in the package must describe the same operation.
How to avoid delays:
Licenses renew, most of them annually. Changes in ownership, facility location, or designated representative must be reported to each state within that state’s deadline. Some changes require a new application rather than a notice. Treating a change that requires a new application as a simple notice means operating without a valid license.
Two ongoing obligations require particular attention:
Clients and their trading partners verify 3PL licenses using state databases and FDA’s licensure lookup. An expired license stops shipments for every client using that facility until the license is reinstated.
FDA’s national standards will change this framework once they are final. Until then, 3PLs must manage licensing state by state, and the most reliable way to do that is to make license review part of client onboarding and facility planning.
Determining which states require licensure, which license category applies, and what each application demands is a complex, high-stakes process for 3PLs operating across multiple jurisdictions.
LighthouseAI's Rapid Assessments identify exactly where your facility needs to be licensed across all 56 US jurisdictions, so you can build a compliant licensing strategy from the ground up.
Know where you need to be licensed before it becomes a problem.
Sandy Carter is Director of Intelligence, Research and Development at LighthouseAI with over a decade of experience in the pharmaceutical life sciences industry. She specializes in regulatory compliance research and analysis across the pharmaceutical sector. Sandy focuses on developing high-quality compliance insights and research methodologies that help organizations navigate complex regulatory frameworks and maintain compliance throughout the pharmaceutical supply chain.
.svg){kind=small}
